NERI and ProMedica CRC Form Strategic Alliance to Support Phase I-IV Clinical Research Studies

WATERTOWN, Mass. & BOSTON--(Business Wire)--
New England Research Institutes, Inc. (NERI), a global contract research
organization (CRO) focused on Phase II-IV clinical trials and ProMedica Clinical
Research Center (CRC), Inc., a dedicated Phase I firm, today announced their
strategic alliance. As a result of this new working relationship, both companies
can now provide pharmaceutical, medical device, biomaterial and biotechnology
clients with seamless and comprehensive clinical research solutions for Phase
I-IV studies in a variety of therapeutic areas.

"Together with ProMedica CRC we are now able to provide expanded CRO services to
clinical sponsors that are looking to build long-term relationships," said
Rebecca Li, Ph.D., Vice President of Clinical Research, NERI. "With the addition
of ProMedica CRC`s hands-on Phase I research capabilities; we can now
collectively transition the in-depth knowledge of an investigational drug or
device into a next Phase of research" said Li. "Clients will benefit from our
combined service efficiencies and continued scientific integrity."

Located in Boston`s thriving medical community, both NERI and ProMedica CRC have
access to best in class scientific talent. With complementary philosophies
around customized service offerings and scientific innovation, the new strategic
alliance is poised to immediately meet client needs.

"We know that our Phase I research experience combined with NERI`s Phase II-IV
track record will provide our clients with a comprehensive portfolio of services
to choose from," said Richard Parker, Founder and CEO, ProMedica CRC. "Through
this strategic alliance we offer an expanded and committed team of professionals
to tackle any clinical research challenge with consistent standards of
excellence."

In addition to each of their respective specialized capabilities, NERI and
ProMedica CRC will have all the resources necessary to respond to a broader
spectrum of client needs. As a result of the working relationship, clients can
benefit from NERI services like study feasibility, protocol design, project
management, regulatory affairs, clinical monitoring and training, biostatistics,
data management, site selection, recruitment, and management, and quality
assurance. In addition to these areas of expertise, ProMedica CRC`s capabilities
include: bioavailability, bioequivalence, pharmacodynamics, pharmacokinetics,
tolerance, toxicity, gastrointestinal absorption, interaction and first in man
studies.

About NERI:

NERI is a full-service Contract Research Organization (CRO) that provides
customized, global clinical trial solutions and patient registry services to
pharmaceutical, biotechnology, biomaterial and medical device companies. NERI
also has notable experience collaborating on federally-funded research with
organizations like the National Institutes of Health (NIH). NERI has a solid
reputation for delivering superior quality and trusted results to each of its
valued clients. Since its founding in 1986, NERI has earned widespread
recognition for its scientific credibility, efficiency and expertise in the
successful conduct of clinical trials. For more information, visit
www.neriscience.com.

About ProMedica CRC:

ProMedica CRC`s mission is to completely satisfy its customers with a corporate
commitment to scientific integrity and reliability to clinical research by
focusing on conducting One Study at a Time. This unique approach affords
ProMedica CRC the opportunity to devote its full resources to each specific
project avoiding the compromise of any study variable. This individual focus
fits the company`s zero-error objective, a goal that clients appreciate. Quality
is ProMedica CRC`s primary goal. For more information, visit
www.promedicacrc.com.

NERI
Karen Barzilay, 508-794-1039
kbarzilay@neriscience.com

Copyright Business Wire 2009